Chemi Pharmaceutical Inc. Enters into Collaboration Agreement with Revive Therapeutics for Research, Development and Analytical Testing of Medical Cannabis

MISSISSAUGA, ONTARIO–(Dec. 18, 2017) – Chemi Pharmaceutical Inc. (“Chemi Pharma” or the “Company”), a company focused on the analytical testing and research and development for the healthcare sector, is pleased to announce that the Company has entered into a collaboration agreement (the “Agreement”) with Revive Therapeutics Ltd. (“Revive”) (TSX VENTURE:RVV)(OTCQB:RVVTF), for the research, development and analytical testing of medical cannabis.  The Agreement with Revive positions Chemi Pharma’s commitment to the medical cannabis market and opens opportunities for Chemi Pharma to expand on its operations and build on its core competencies in research and analytical testing.

“We are very excited to collaborate with Revive on its initiatives of advancing novel medical cannabis products and technologies that leverages our core competencies and passion for healthcare solutions, including medical cannabis,” said Emil Stavrikov, Chief Executive Officer and Founder of Chemi Pharma. “We look forward to advancing our relationship with Revive and the potential of our next phase of growth in our businesses.”

“We are very excited with our collaboration with Chemi Pharma as it serves as an important part of our strategy in becoming a global leader in the medical cannabis industry while unlocking opportunities in partnering with pharmaceutical companies and licensed producers of medical cannabis,” said Fabio Chianelli, President of Revive. “We have an established relationship with Chemi Pharma and their commitment to quality research and testing under GMP and GLP paves the way for valuable opportunities in the medical cannabis market, which are only made available with a Dealer’s License. Revive is also exploring the potential of developing novel cannabis testing products and services that may be enabled by blockchain and artificial intelligence.”

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV)(OTCQB:RVVTF) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors. Additional information on Revive is available at

About Chemi Pharmaceutical Inc.

Founded in 2001, Chemi Pharma serves the Pharmaceutical, Natural Health Product, Cosmetics, Veterinary, and Cannabis industries with a wide range of quality control analytical testing and research and development services under Good Manufacturing Practice (“GMP”) and Good Laboratory Practice (“GLP”). Chemi Pharma is a Licensed Dealer pursuant to the Controlled Drugs and Substances Act under Health Canada and holds an Establishment License from Health Canada and Inspections from U.S. Food and Drug Administration. Additional information on Chemi Pharma is available at

Chemi Pharmaceutical Inc celebrates 15th Anniversary!

July 9, 2016, Mississauga, ON – Chemi Pharmaceutical Inc. is proud to announce its fifteenth year as a leading provider of GMP analytical services. We wish to share this moment with our customers, partners and friends, and thank you all for your support throughout the years. We could not have done it without you! We wish to continue to grow our business by providing you with the best possible analytical solutions and services. May our family of companies grow together!

Chemi Pharmaceutical attended PSG’s 43rd Annual Pharmaceutical Symposium and Exhibition

Chemi Pharmaceutical attended PSG’s 43rd Annual Pharmaceutical Symposium and Exhibition on Recent Advances in Pharmaceuticals, Medical Devices & Biosimilars on May 10, 2016.

We would like to thank our friends and partners for stopping by our booth to chat with our CEO, President and company representatives. We look forward to see you again!

PSG Annual Conference               PSG Annual Conference 1                 PSG Conf


Annual Conference



FDA Statement on Proposed Action Level for Inorganic Arsenic in Infant Rice Cereal

Arsenic is an element in the Earth’s crust and is present in water, air and soil. Fertilizers and pesticides also contribute to levels. Arsenic exists in two forms, organic and inorganic. When encountered in the diet, inorganic arsenic is considered to be the more toxic of the two forms.

Rice has higher levels of inorganic arsenic than other foods, in part because as rice plants grow, the plant and grain tend to absorb arsenic from the environment more than other crops. Arsenic is not intentionally added to rice grain, and when present in the grain, cannot be completely removed.

The FDA has been monitoring the levels of arsenic in foods and in 2011, after new methods to differentiate the forms of arsenic became available, the agency expanded its testing to help better understand and manage possible arsenic-related risks associated with food consumption in the United States.

Based on its testing, the FDA on April 1, 2016 proposed an action level, or limit, of 100 parts per billion (ppb) for inorganic arsenic in infant rice cereal. This level, which is based on the FDA’s assessment of a large body of scientific information, seeks to reduce infant exposure to inorganic arsenic. Relative to body weight, rice intake for infants, primarily through infant rice cereal, is about three times greater than for adults.

In response to rising levels of toxic elements in soil used for agriculture and consumer products, Chemi Pharmaceutical has acquired a state of the art qualified GMP ICP-MS with digestive microwave that can trace all elements in the periodic table to a trillion of a gram. Chemi Pharmaceutical expects interest in such testing to grow as a result of increased regulation and public awareness of the effects of heavy metals on human health.


Source: FDA, April 1, 2016